SureTrader Stock Hero Advertisement SPDR Advertisement
Home > Boards > US Listed > Medical - Drugs >

RXI Pharmaceuticals Corp (RXII)

Add RXII Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator pistol1p
Search This Board:
Last Post: 2/28/2015 10:41:35 AM - Followers: 72 - Board type: Free - Posts Today: 0

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.  Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.  Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human clinical trial in 2012.  RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.


RXi Pharmaceuticals Corp., has received patent approval for their new experimental breast cancer vaccine which became part of the company's arsenal after acquiring Apthera Inc. in April of this year.
The specific patents in question regard using the vaccine NeuVax with the drug Herceptin which is used in women to slow the production of the HER2 protein in tumors, while NeuVax attempts to make the body's immune system fight off cancerous cells.
According to The Telegram:
"The patents also cover using NeuVax in patients not eligible for Herceptin treatment."
With their patent in place the company plans to begin human tests in early 2012.
According to RXi the patents were developed by Dr. George E. Peoples, director of the Cancer Vaccine Development Program for the U.S. Military Cancer Institute and RXi is leasing the patents for their own work.


This May, RXi Pharmaceuticals Corp. observed two momentous events: The biotechnology company completed its spinoff from Galena Biopharma Inc., and Dr. Geert Cauwenbergh took the helm as president and chief executive officer. The small company's first product, an anti-scarring medication called RXI-109, entered clinical trials this year, and is based on the pioneering work in RNA interference of RXi scientific founder and Nobel Laureate Dr. Craig C. Mello. Dr. Cauwenbergh came to RXi after a long career in pharmaceuticals, most recently as president and chief executive officer of a company he founded, Barrier Therapeutics. What attracted you to come to Worcester? "It was the technology, well, the technology and the chemistry with these people. They're very bright." As a publicly traded company, how do you reconcile the needs of the investors, which are sometimes a short-term desire for profits, with the needs of medical research, which sometimes takes years? "Through business development. Basically what you do as a small biotech is you try to create a big network with people who have interest in various stages of development. ... In two or three years they get antsy and they want to cash in, but at that point in time there will be and there is already a network of business development contacts in place where you can for instance get nondiluted money without having to raise money and go back to the stock market and shareholders by making regional deals or geographic deals ...


Dec 17, 2014 RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

Press Releases
RXi Pharmaceuticals to Present at Biotech Showcase™ 2013 - December 19, 2012
RXi Pharmaceuticals Announces Initiation of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109 - December 5, 2012
RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers - November 15, 2012
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 - November 14, 2012
RXi Pharmaceuticals to Present at 12th Annual Biotech Symposium - October 16, 2012
RXi Pharmaceuticals Awarded NCI SBIR Funding to Advance Self-Delivering RNAi Technology - October 4, 2012
RXi Pharmaceuticals to Present at 11th Annual BIO Investor Forum - October 2, 2012
RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program - September 24, 2012
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2012 - August 15, 2012
RXi Pharmaceuticals Appoints Jeannette Graf MD and Leroy Young MD to its Scientific Advisory Board - July 13, 2012
Share Statistics
Avg Vol (3 month)3: 215,443
Avg Vol (10 day)3: 145,371
Shares Outstanding5: 338m
Float: 53.34M
% Held by Insiders1: 9.01%
% Held by Institutions1: 0.50%

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
RXII News: RXi Pharmaceuticals Issues Open Letter to Shareholders 12/22/2014 07:02:00 AM
RXII News: RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of En... 12/17/2014 07:02:00 AM
RXII News: RXi Pharmaceuticals to Present New Data in its First Phase 2a Clinical Trial with RXI-109 10/07/2014 07:02:00 AM
RXII News: RXi Pharmaceuticals Presented an Update on the Company's Dermatology and Ophthalmology Franchises 09/11/2014 07:02:00 AM
#1646   Lol good one! Titan V 02/28/15 10:41:35 AM
#1645   No, that was the other Other Guy! The Other Guy 02/26/15 10:24:50 PM
#1644   Agreed. On a sidenote, did you shoot Jeter? Titan V 02/26/15 08:02:15 PM
#1643   I would prefer a higher percentage of II The Other Guy 02/26/15 01:14:56 PM
#1642   Thanks for sharing. I'm pretty hopeful on RXII Titan V 02/26/15 11:55:07 AM
#1641   Okay, so I spent a bit of time The Other Guy 02/26/15 10:40:48 AM
#1640   Anyone here know the potential market of Samcyprone? The Other Guy 02/25/15 12:58:13 PM
#1639   Plenty of value here with phase 2 trials pistol1p 02/09/15 09:18:43 PM
#1638   It's interesting that Dr. Pavco will be speaking Titan V 02/06/15 10:30:38 PM
#1637   Company's Chief Development Officer, Dr. Pamela Pavco, will pistol1p 02/06/15 08:33:49 PM
#1636   RXi Pharmaceuticals Announces Closing of the Exclusive Global tomsylver 02/05/15 01:27:21 PM
#1635   This news is huge patent for wet age-related Inoviorulez 02/03/15 07:28:22 AM
#1634   RXi Pharmaceuticals to Present at the 17th Annual Inoviorulez 02/02/15 07:17:36 AM
#1633   RXII is on a comeback . Another green day T695 01/22/15 09:37:56 AM
#1632   This could easily go back to 1.60 IMO T695 01/22/15 06:24:51 AM
#1631   Wild ride in the last two days. pistol1p 01/21/15 08:20:48 PM
#1630   A little more volume might get this back T695 01/21/15 12:54:18 PM
#1629   Still bouncing from yesterday. RXII T695 01/21/15 09:39:42 AM
#1628   Dead cat bounce. dubbya 01/20/15 01:50:57 PM
#1627   Disclosure: i have about 5k shares of RXII. value1008 01/20/15 01:20:55 PM
#1626   Well it's up over 10% since I posted that T695 01/20/15 12:00:08 PM
#1625   It went from 2.00 to 1.00 in a dubbya 01/20/15 11:07:00 AM
#1624   This about to take off IMO T695 01/20/15 10:28:50 AM
#1623   RXi Pharmaceuticals to Present at the 7th Annual tomsylver 01/05/15 10:56:42 AM
#1622   Volume has been steady, but the PPS has pistol1p 01/02/15 11:55:34 PM
#1621   Source: seeking alpha RXi Pharmaceuticals: Stock Appears On Sale tomsylver 12/24/14 11:41:37 AM
#1620   Added myself yesterday..I like the science,the pps and the submariner 12/23/14 06:33:40 AM
#1619   Nice paint job, taking the pps down from pistol1p 12/22/14 08:05:22 PM
#1618   I added today... and if it goes south now invest 12/22/14 07:57:53 PM
#1617   RXi Pharmaceuticals Issues Open Letter to Shareholders Company Release tomsylver 12/22/14 05:01:34 PM
#1616   Whoa, glad I got out yesterday. dubbya 12/19/14 02:27:11 PM
#1615   RXi Pharmaceuticals Expands its Clinical Pipeline with an tomsylver 12/19/14 10:44:05 AM
#1614   "..blinded evaluators were able to identify accurately the dubbya 12/18/14 11:04:30 AM
#1613   RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at tomsylver 12/18/14 04:27:28 AM
#1612   A little profit-taking today, followed by an end pistol1p 11/28/14 01:10:57 PM
#1611   Any comments on the price action today and pistol1p 11/26/14 09:01:48 PM
#1610   Nice strength into close. Parabolic SAR finally switched value1008 11/26/14 04:12:55 PM
#1609   Shorty will try to push the pps down pistol1p 11/26/14 03:22:08 PM
#1608   Nice run this am. pistol1p 11/26/14 02:37:05 PM
#1607   21m. Was16m until a couple of months ago. Titan V 11/23/14 11:04:28 PM
#1606   How many shares o/s does this have? There kruy 11/23/14 10:22:11 PM
#1605   Seeking alpha: Update: RXi Pharmaceuticals Reports Q3 Earnings; My tomsylver 11/17/14 11:13:38 PM
#1604   RXi Pharmaceuticals Reports Financial Results for the Third tomsylver 11/13/14 02:46:03 PM
#1603   website and financial statement press release..... 123tom 11/13/14 02:14:34 PM
#1602   The technical chart pattern now.... 123tom 11/12/14 05:47:59 PM
#1601   Low volume for most of the last couple pistol1p 11/04/14 12:23:38 AM
#1600   Its truly a bummer for you so far. JDLAXXE 11/04/14 12:21:15 AM
#1599   Hey, I've held this from $5.50 of 1k 1 million 11/03/14 05:55:03 PM
#1598   lol.....looks like the street wasn't impressed at all.... Myth 11/03/14 10:13:47 AM
#1597   Should be. Was above 3 before the 1 Titan V 11/02/14 11:32:22 PM